SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-012869 to Disc Medicine, Inc. (IRON) (CIK 0001816736) (IRON)

Disc Medicine, Inc. (IRON) (CIK 0001816736)
Date: Nov. 27, 2023 · CIK: 0001816736 · Accession: 0000000000-23-012869

AI Filing Summary & Sentiment

File numbers found in text: 333-275652

Date
November 27, 2023
Author
Not clearly detected
Form
UPLOAD
Company
Disc Medicine, Inc. (IRON) (CIK 0001816736)

Letter

United States securities and exchange commission logo November 27, 2023 Dr. John Quisel Chief Executive Officer Disc Medicine, Inc. 321 Arsenal Street, Suite 101 Watertown, MA 02472 Re:Disc Medicine, Inc. Registration Statement on Form S-3 Filed November 20, 2023 File No. 333-275652 Dear Dr. John Quisel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephanie Richards, Esq.

Show Raw Text
United States securities and exchange commission logo
November 27, 2023
Dr. John Quisel
Chief Executive Officer
Disc Medicine, Inc.
321 Arsenal Street, Suite 101
Watertown, MA 02472
Re:Disc Medicine, Inc.
Registration Statement on Form S-3
Filed November 20, 2023
File No. 333-275652
Dear Dr. John Quisel:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:        Stephanie Richards, Esq.